6:2 influenza virus reassortant vaccine

The **6:2 influenza virus reassortant vaccine** is a type of influenza vaccine seed virus manufactured by reassortment techniques, classically utilizing *6 internal gene segments* from a high-yield laboratory influenza "backbone" virus and *2 surface glycoprotein gene segments*—hemagglutinin (HA) and neuraminidase (NA)—from the current circulating seasonal strain. This 6:2 genomic configuration is used to produce vaccine viruses with optimal growth properties and appropriate antigenicity for seasonal influenza vaccine production, especially in egg-based and cell-based vaccines. Mechanistically, the vaccine provides immunity by inducing an immune response against the HA and NA antigens, thus targeting the surface proteins of circulating influenza viruses. The process was initially performed via classical co-infection and antibody selection methods but may also utilize reverse genetics for more efficient seed virus generation. Primary indication is the *prevention of seasonal influenza* via immunization[2][6].

Other names

6:2 reassortant influenza vaccine6:2 reassortant virus seed